Hematopoietic Cell Transplantation for Primary Systemic Amyloidosis

This policy covers autologous hematopoietic cell transplantation (HCT), performed after high‑dose chemotherapy with or without total‑body irradiation, as a medically necessary treatment to reduce amyloidogenic light chains and restore marrow function in patients with primary systemic (AL) amyloidosis. Coverage is limited to eligible patients who are medically fit for intensive conditioning (organ dysfunction—especially symptomatic cardiac involvement or multi‑organ disease—may preclude high‑toxicity regimens); allogeneic HCT is considered experimental/uncovered, and donor HLA matching/conditioning requirements apply when allo‑HCT is considered.

"Hematopoietic cell transplantation (HCT) for primary systemic (AL) amyloidosis"

Sign up to see full coverage criteria, indications, and limitations.